≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Congenital ichthyosis

DOID EFO Endpoint Browser PheWeb

Q17_CONGEN_ICHTHYOSIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q80
  • Cause of death: ICD-10 — Q80

2 out of 7 registries used, show all original rules.

113

4. Check minimum number of events

None

113

5. Include endpoints

None

113

6. Filter based on genotype QC (FinnGen only)

112

Control definitions (FinnGen only)

Control exclude
Q17_OTHER_CONGEN_MALFO

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Q8
Name in latin
Ichthyosis congenita

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1177 430 744
Only index persons 1017 379 638
Unadjusted period prevalence (%)
Whole population 0.02 0.01 0.02
Only index persons 0.02 0.01 0.02
Median age at first event (years)
Whole population 19.16 24.30 16.03
Only index persons 20.43 25.76 17.26

-FinnGen-

Key figures

All Female Male
Number of individuals 112 56 56
Unadjusted period prevalence (%) 0.02 0.02 0.03
Median age at first event (years) 35.99 38.68 33.30

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
113
Matched controls
1130
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D02AE01
ATC
carbamide; topical
24.1
60.6
53
40
Q80.9
ICD-10 Finland
Congenital ichthyosis, unspecified
697.2
48.1
44
*
Q80.0
ICD-10 Finland
Ichthyosis vulgaris
+∞
47.2
42
*
E000006, ,
ATC
19.8
39.1
34
24
Q80.8
ICD-10 Finland
Other congenital ichthyosis
+∞
27.2
25
*
E000001, ,
ATC
7.1
24.5
60
156
E0000UV, ,
ATC
8.6
23.3
90
354
Q80.1
ICD-10 Finland
X-linked ichthyosis
+∞
22.7
21
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
10.3
21.9
28
35
E000002, ,
ATC
7.3
20.0
37
71
Q80.2
ICD-10 Finland
Lamellar ichthyosis
+∞
18.2
17
*
D05BB02
ATC
acitretin; oral
25.0
13.9
19
9
75720
ICD-8 Finland
Congenital anomalies of skin, hair and nails, Iethyosis congenita
+∞
12.7
12
*
E000003, ,
ATC
12.2
12.7
23
23
D07AB08
ATC
desonide; topical
5.2
11.6
28
67
134
Kela drug reimbursment
General erythroderma
120.8
10.6
11
*
Q80.3
ICD-10 Finland
Congenital bullous ichthyosiform erythroderma
+∞
10.6
10
*
Z31.5
ICD-10 Finland
Genetic counselling
7.6
9.0
21
33
D02AX
ATC
Other emollients and protectives
9.8
8.7
17
20
G80.2
ICD-10 Finland
Spastic hemiplegic cerebral palsy
+∞
8.4
8
*
G80.1
ICD-10 Finland
Spastic diplegic cerebral palsy
+∞
8.4
8
*
TQW80
NOMESCO Finland
Local dermatologic skincare
13.2
7.8
13
11
E000007, ,
ATC
6.5
7.1
18
32
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
4.2
6.5
19
52
D07AB02
ATC
hydrocortisone butyrate; topical
2.8
6.2
44
210
D07XC01
ATC
betamethasone; topical
3.8
6.1
20
60

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
4.3e-01
8.7e-01
1.0e+00
6.3e+00
1.7e+00
2.0e+00
2.4e+00
cases:62.50%
controls:52.05%
cases:58.10%
controls:36.83%
cases:23.81%
controls:10.20%
cases:73.33%
controls:0.49%
cases:34.29%
controls:8.75%
cases:82.52%
controls:39.71%
cases:95.96%
controls:68.23%
65
532
39
490
61
379
44
650
25
105
80
924
77
5
28
1024
36
90
69
939
85
407
18
618
95
655
4
305
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.2e+00
2.3e+00
—
1.0e+50
—
3.9e+00
2.4e+00
cases:15.38%
controls:4.99%
cases:15.24%
controls:1.75%
—
—
cases:62.86%
controls:0.00%
—
—
cases:49.51%
controls:1.95%
cases:44.44%
controls:6.46%
16
51
88
971
16
18
89
1011
—
66
0
39
1029
—
51
20
52
1005
44
62
55
898
Inpatient Hospital
21 [8717]
3.3e-01
1.1e+00
2.2e+00
—
2.1e+00
1.2e+00
9.1e-01
cases:39.42%
controls:31.90%
cases:25.71%
controls:10.01%
cases:6.67%
controls:0.78%
—
—
cases:7.62%
controls:0.97%
cases:21.36%
controls:7.80%
cases:47.47%
controls:26.67%
41
326
63
696
27
103
78
926
7
8
98
1021
—
8
10
97
1019
22
80
81
945
47
256
52
704
Pharmacy visit
OMOP4822462 [581458]
9.9e-01
1.4e+00
6.3e-01
1.9e+00
9.7e-01
2.8e+00
1.3e+00
cases:96.15%
controls:90.31%
cases:91.43%
controls:72.69%
cases:47.62%
controls:32.56%
cases:7.62%
controls:1.26%
cases:58.10%
controls:34.50%
cases:98.06%
controls:75.32%
cases:97.98%
controls:93.23%
100
923
4
99
96
748
9
281
50
335
55
694
8
13
97
1016
61
355
44
674
101
772
2
253
97
895
2
65
Psychiatry
26 [38004469]
1.4e+00
1.4e+00
—
—
—
2.2e+00
1.4e+00
cases:9.62%
controls:2.54%
cases:4.76%
controls:1.17%
—
—
—
—
—
—
cases:7.77%
controls:0.88%
cases:14.14%
controls:3.96%
10
26
94
996
5
12
100
1017
—
—
—
8
9
95
1016
14
38
85
922
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
2.3e+00
2.3e+00
—
—
—
2.5e+00
1.8e+00
cases:6.73%
controls:0.68%
cases:4.76%
controls:0.49%
—
—
—
—
—
—
cases:5.83%
controls:0.49%
cases:5.05%
controls:0.83%
7
7
97
1015
5
5
100
1024
—
—
—
6
5
97
1020
5
8
94
952
Office Visit
OMOP4822458 [581477]
9.4e-01
1.4e+00
—
—
—
2.1e+00
1.3e+00
cases:15.38%
controls:6.65%
cases:10.48%
controls:2.72%
—
—
—
—
—
—
cases:16.50%
controls:2.24%
cases:27.27%
controls:9.58%
16
68
88
954
11
28
94
1001
—
—
—
17
23
86
1002
27
92
72
868
Paediatric neurology
421 [44777781]
1.9e+00
2.2e+00
—
—
—
1.9e+00
1.6e+00
cases:6.73%
controls:1.08%
cases:5.71%
controls:0.68%
—
—
—
—
—
—
cases:4.85%
controls:0.78%
cases:7.07%
controls:1.56%
7
11
97
1011
6
7
99
1022
—
—
—
5
8
98
1017
7
15
92
945
hydrocortisone buteprate
D07AB11 [21602115]
7.4e-01
1.4e+00
—
—
—
1.5e+00
1.2e+00
cases:11.54%
controls:5.87%
cases:9.52%
controls:2.43%
—
—
—
—
—
—
cases:9.71%
controls:2.44%
cases:19.19%
controls:6.98%
12
60
92
962
10
25
95
1004
—
—
—
10
25
93
1000
19
67
80
893
hydrocortisone butyrate
D07AB02 [21602106]
7.4e-01
1.4e+00
—
—
—
1.5e+00
1.2e+00
cases:11.54%
controls:5.87%
cases:9.52%
controls:2.43%
—
—
—
—
—
—
cases:9.71%
controls:2.44%
cases:19.19%
controls:6.98%
12
60
92
962
10
25
95
1004
—
—
—
10
25
93
1000
19
67
80
893
hydrocortisone
D07AA02 [21602102]
7.4e-01
1.4e+00
—
—
—
1.5e+00
1.2e+00
cases:11.54%
controls:5.87%
cases:9.52%
controls:2.43%
—
—
—
—
—
—
cases:9.71%
controls:2.44%
cases:19.19%
controls:6.98%
12
60
92
962
10
25
95
1004
—
—
—
10
25
93
1000
19
67
80
893
hydrocortisone aceponate
D07AC16 [21602135]
7.4e-01
1.4e+00
—
—
—
1.5e+00
1.2e+00
cases:11.54%
controls:5.87%
cases:9.52%
controls:2.43%
—
—
—
—
—
—
cases:9.71%
controls:2.44%
cases:19.19%
controls:6.98%
12
60
92
962
10
25
95
1004
—
—
—
10
25
93
1000
19
67
80
893
hydrocortisone
A07EA02 [21600654]
7.2e-01
1.4e+00
—
—
—
1.4e+00
1.2e+00
cases:11.54%
controls:5.97%
cases:9.52%
controls:2.43%
—
—
—
—
—
—
cases:9.71%
controls:2.54%
cases:19.19%
controls:6.98%
12
61
92
961
10
25
95
1004
—
—
—
10
26
93
999
19
67
80
893
hydrocortisone
C05AA01 [21601608]
7.2e-01
1.4e+00
—
—
—
1.4e+00
1.2e+00
cases:11.54%
controls:5.97%
cases:9.52%
controls:2.43%
—
—
—
—
—
—
cases:9.71%
controls:2.54%
cases:19.19%
controls:6.98%
12
61
92
961
10
25
95
1004
—
—
—
10
26
93
999
19
67
80
893
Case Management Agency
251B00000X [38004193]
3.2e-01
1.3e-01
4.7e-01
3.5e+00
2.0e-01
2.1e-01
4.4e-01
cases:44.23%
controls:36.50%
cases:33.33%
controls:30.42%
cases:18.10%
controls:12.15%
cases:14.29%
controls:0.49%
cases:14.29%
controls:12.05%
cases:37.86%
controls:33.07%
cases:66.67%
controls:56.25%
46
373
58
649
35
313
70
716
19
125
86
904
15
5
90
1024
15
124
90
905
39
339
64
686
66
540
33
420
Scheduled procedure
ZXD10 [2001311387]
1.4e+00
2.1e+00
—
—
—
—
8.4e-01
cases:12.50%
controls:3.42%
cases:6.67%
controls:0.87%
—
—
—
—
—
—
—
—
cases:11.11%
controls:5.10%
13
35
91
987
7
9
98
1020
—
—
—
—
11
49
88
911
combinations of corticosteroids
D07XB30 [21602188]
7.3e-01
1.2e+00
—
—
—
1.8e+00
1.3e+00
cases:16.35%
controls:8.61%
cases:9.52%
controls:3.21%
—
—
—
—
—
—
cases:13.59%
controls:2.44%
cases:26.26%
controls:8.75%
17
88
87
934
10
33
95
996
—
—
—
14
25
89
1000
26
84
73
876
combinations of corticosteroids
D07AB30 [21602118]
7.3e-01
1.2e+00
—
—
—
1.8e+00
1.3e+00
cases:16.35%
controls:8.61%
cases:9.52%
controls:3.21%
—
—
—
—
—
—
cases:13.59%
controls:2.44%
cases:26.26%
controls:8.75%
17
88
87
934
10
33
95
996
—
—
—
14
25
89
1000
26
84
73
876
carbamide
D02AE01 [21601975]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.08%
controls:0.52%
—
—
—
—
—
—
8
5
91
955
hydrocortisone
S02BA01 [21605166]
5.9e-01
1.3e+00
—
—
—
1.5e+00
1.2e+00
cases:9.62%
controls:5.58%
cases:7.62%
controls:2.14%
—
—
—
—
—
—
cases:8.74%
controls:2.05%
cases:18.18%
controls:6.25%
10
57
94
965
8
22
97
1007
—
—
—
9
21
94
1004
18
60
81
900
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
—
—
—
1.0e+50
—
1.0e+50
2.6e+00
—
—
—
—
—
—
cases:6.67%
controls:0.00%
—
—
cases:7.77%
controls:0.00%
cases:9.09%
controls:0.73%
—
—
—
7
0
98
1029
—
8
0
95
1025
9
7
90
953
Otolaryngology
4 [38004449]
6.3e-01
1.1e+00
—
—
—
1.4e+00
1.0e+00
cases:15.38%
controls:8.81%
cases:10.48%
controls:3.89%
—
—
—
—
—
—
cases:10.68%
controls:2.73%
cases:23.23%
controls:9.69%
16
90
88
932
11
40
94
989
—
—
—
11
28
92
997
23
93
76
867
Bilateral
ZXA10 [2001311348]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:0.73%
—
—
—
—
—
—
7
7
92
953
cefalexin; oral
J01DB01 [21602870]
3.9e-01
1.1e+00
—
—
—
1.1e+00
4.5e-01
cases:32.69%
controls:24.66%
cases:19.05%
controls:7.00%
—
—
—
—
—
—
cases:19.42%
controls:7.51%
cases:36.36%
controls:26.67%
34
252
70
770
20
72
85
957
—
—
—
20
77
83
948
36
256
63
704
Tissue Pathology biopsy report
66121-5 [40768804]
—
—
—
—
—
2.2e+00
9.0e-01
—
—
—
—
—
—
—
—
—
—
cases:6.80%
controls:0.78%
cases:8.08%
controls:3.44%
—
—
—
—
—
7
8
96
1017
8
33
91
927
General Surgery
2 [38004447]
4.4e-01
—
—
—
1.5e+00
1.2e+00
9.6e-01
cases:20.19%
controls:13.99%
—
—
—
—
—
—
cases:4.76%
controls:1.07%
cases:17.48%
controls:5.76%
cases:32.32%
controls:15.52%
21
143
83
879
—
—
—
5
11
100
1018
18
59
85
966
32
149
67
811
Plastic And Reconstructive Surgery
24 [38004467]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:1.15%
—
—
—
—
—
—
9
11
90
949
hydroxyzine; oral, parenteral
N05BB01 [21604590]
1.9e+00
—
—
—
—
—
1.6e+00
cases:6.73%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.04%
7
11
97
1011
—
—
—
—
—
5
10
94
950
Medical doctor
Z2221 [2001311556]
9.4e-01
1.9e+00
—
—
—
1.5e+00
1.0e+00
cases:6.73%
controls:2.74%
cases:6.67%
controls:1.07%
—
—
—
—
—
—
cases:4.85%
controls:1.07%
cases:7.07%
controls:2.71%
7
28
97
994
7
11
98
1018
—
—
—
5
11
98
1014
7
26
92
934
Differential panel, method unspecified - Blood
69738-3 [42870588]
—
1.2e+00
—
—
—
1.8e+00
1.0e+00
—
—
cases:5.71%
controls:1.85%
—
—
—
—
—
—
cases:6.80%
controls:1.17%
cases:9.09%
controls:3.54%
—
6
19
99
1010
—
—
—
7
12
96
1013
9
34
90
926
Audiology
64 [38004489]
1.8e+00
—
—
—
—
—
—
cases:7.69%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
8
14
96
1008
—
—
—
—
—
—
Asthma, unspecified
J45.9 [45562456]
1.8e+00
—
—
—
—
—
1.4e+00
cases:9.62%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
cases:9.09%
controls:2.50%
10
18
94
1004
—
—
—
—
—
9
24
90
936
clindamycin; oral, parenteral
J01FF01 [21602985]
1.7e+00
—
—
—
—
—
—
cases:7.69%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
—
—
8
15
96
1007
—
—
—
—
—
—
other preparations, combinations; ointment
C05AX03 [21601631]
7.4e-01
—
—
—
—
—
1.7e+00
cases:4.81%
controls:2.35%
—
—
—
—
—
—
—
—
—
—
cases:12.12%
controls:2.50%
5
24
99
998
—
—
—
—
—
12
24
87
936
chlorhexidine
S03AA04 [21605193]
1.5e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.19%
6
14
98
1008
—
—
—
—
—
10
21
89
939
chlorhexidine
D09AA12 [21602275]
1.5e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.19%
6
14
98
1008
—
—
—
—
—
10
21
89
939
hydrocortisone
D07XA01 [21602180]
1.5e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.19%
6
14
98
1008
—
—
—
—
—
10
21
89
939
chlorhexidine
S02AA09 [21605155]
1.5e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.19%
6
14
98
1008
—
—
—
—
—
10
21
89
939
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
1.5e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.19%
6
14
98
1008
—
—
—
—
—
10
21
89
939
hydrocortisone and antiseptics
D07BA04 [21602146]
1.5e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.19%
6
14
98
1008
—
—
—
—
—
10
21
89
939
chlorhexidine, combinations
D08AC52 [21602208]
1.5e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.19%
6
14
98
1008
—
—
—
—
—
10
21
89
939
triamcinolone and antiseptics
D07BB03 [21602150]
1.4e+00
—
—
—
—
—
1.6e+00
cases:5.77%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.29%
6
15
98
1007
—
—
—
—
—
10
22
89
938
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:1.26%
—
—
—
—
—
—
—
—
cases:10.10%
controls:2.29%
—
0
13
105
1016
—
—
—
—
10
22
89
938
Neurology
13 [38004458]
2.7e-01
1.0e+00
—
—
—
1.4e+00
8.7e-01
cases:7.69%
controls:5.97%
cases:7.62%
controls:2.92%
—
—
—
—
—
—
cases:10.68%
controls:2.83%
cases:15.15%
controls:6.98%
8
61
96
961
8
30
97
999
—
—
—
11
29
92
996
15
67
84
893
zopiclone; oral
N05CF01 [21604654]
1.4e+00
9.7e-01
—
—
—
1.4e+00
1.1e+00
cases:12.50%
controls:3.42%
cases:6.67%
controls:2.62%
—
—
—
—
—
—
cases:9.71%
controls:2.63%
cases:10.10%
controls:3.75%
13
35
91
987
7
27
98
1002
—
—
—
10
27
93
998
10
36
89
924
General Practice
1 [38004446]
3.0e-01
1.4e+00
—
—
—
1.1e+00
7.0e-01
cases:8.65%
controls:6.56%
cases:11.43%
controls:3.21%
—
—
—
—
—
—
cases:7.77%
controls:2.63%
cases:19.19%
controls:10.52%
9
67
95
955
12
33
93
996
—
—
—
8
27
95
998
19
101
80
859
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
5.2e-01
—
—
—
—
-1.0e+50
1.4e+00
cases:5.77%
controls:3.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
cases:14.14%
controls:4.06%
6
36
98
986
—
—
—
—
0
18
103
1007
14
39
85
921
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
5.2e-01
—
—
—
—
-1.0e+50
1.4e+00
cases:5.77%
controls:3.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
cases:14.14%
controls:4.06%
6
36
98
986
—
—
—
—
0
18
103
1007
14
39
85
921
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
5.8e-01
—
—
—
—
1.4e+00
1.3e+00
cases:5.77%
controls:3.33%
—
—
—
—
—
—
—
—
cases:4.85%
controls:1.27%
cases:12.12%
controls:3.54%
6
34
98
988
—
—
—
—
5
13
98
1012
12
34
87
926
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.3e+00
9.8e-01
—
—
—
-1.0e+50
5.6e-01
cases:12.50%
controls:3.91%
cases:4.76%
controls:1.85%
—
—
—
—
—
—
cases:0.00%
controls:1.46%
cases:7.07%
controls:4.17%
13
40
91
982
5
19
100
1010
—
—
—
0
15
103
1010
7
40
92
920
Supplier / Service Provider
OMOP5117446 [33004]
-1.3e+00
—
—
—
—
—
2.5e+00
cases:7.69%
controls:23.97%
—
—
—
—
—
—
—
—
—
—
cases:8.08%
controls:0.73%
8
245
96
777
—
—
—
—
—
8
7
91
953
fluticasone; nasal
R01AD08 [21605050]
1.1e+00
1.3e+00
—
—
—
1.2e+00
6.3e-01
cases:15.38%
controls:5.77%
cases:7.62%
controls:2.24%
—
—
—
—
—
—
cases:6.80%
controls:2.24%
cases:12.12%
controls:6.88%
16
59
88
963
8
23
97
1006
—
—
—
7
23
96
1002
12
66
87
894
fluticasone furoate; nasal
R01AD12 [21605053]
1.1e+00
1.3e+00
—
—
—
1.2e+00
6.3e-01
cases:15.38%
controls:5.77%
cases:7.62%
controls:2.24%
—
—
—
—
—
—
cases:6.80%
controls:2.24%
cases:12.12%
controls:6.88%
16
59
88
963
8
23
97
1006
—
—
—
7
23
96
1002
12
66
87
894
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.1e+00
—
—
—
-1.0e+50
—
4.7e-01
cases:13.46%
controls:4.99%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
cases:5.05%
controls:3.23%
14
51
90
971
—
—
—
0
5
105
1024
—
5
31
94
929
Internal Medicine
11 [38004456]
3.8e-01
1.0e+00
—
—
—
4.9e-01
6.3e-01
cases:19.23%
controls:13.99%
cases:15.24%
controls:6.12%
—
—
—
—
—
—
cases:10.68%
controls:6.83%
cases:30.30%
controls:18.75%
20
143
84
879
16
63
89
966
—
—
—
11
70
92
955
30
180
69
780
Infiltration anesthesia
WX110 [2001310767]
2.1e-01
1.6e-01
-1.0e+50
—
—
—
8.6e-01
cases:11.54%
controls:9.59%
cases:4.76%
controls:4.08%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:27.27%
controls:13.65%
12
98
92
924
5
42
100
987
0
6
105
1023
—
—
—
27
131
72
829
Cardiodefibrillation
TFP20 [2001303224]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Hand Surgery
40 [38004480]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:1.17%
—
—
—
0
7
105
1022
—
—
—
0
12
103
1013
—
Toxoplasma gondii IgM Ab [Units/volume] in Serum
8040-8 [3027529]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
Vaccination
SPAT1325 [2001700426]
—
—
—
—
-1.0e+50
—
4.1e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
cases:7.07%
controls:4.79%
—
—
—
—
0
7
105
1022
—
7
46
92
914
betamethasone
A07EA04 [21600656]
7.9e-01
—
—
—
—
1.4e+00
8.6e-01
cases:8.65%
controls:4.11%
—
—
—
—
—
—
—
—
cases:7.77%
controls:1.95%
cases:12.12%
controls:5.52%
9
42
95
980
—
—
—
—
8
20
95
1005
12
53
87
907
ethylmorphine; oral
R05DA01 [21603397]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
5
105
1024
—
—
—
—
—
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
5
103
1020
—
Knee symptom/complaint
L15 [2002000639]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
6
105
1023
—
—
—
0
5
103
1020
—
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
104
1014
—
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
Predominantly allergic asthma
J45.0 [45557624]
1.3e+00
—
—
—
—
—
—
cases:4.81%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
5
14
99
1008
—
—
—
—
—
—
Dentistry
C5 [903277]
—
—
—
—
—
—
6.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:2.81%
—
—
—
—
—
—
5
27
94
933
Urology
34 [38004474]
—
-1.0e+50
—
—
—
—
1.4e-01
—
—
cases:0.00%
controls:2.14%
—
—
—
—
—
—
—
—
cases:6.06%
controls:5.31%
—
0
22
105
1007
—
—
—
—
6
51
93
909
almotriptan; oral
N02CC05 [21604380]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
amitriptyline; oral, parenteral
N06AA09 [21604696]
—
-1.0e+50
—
—
—
—
6.5e-01
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
cases:5.05%
controls:2.71%
—
0
10
105
1019
—
—
—
—
5
26
94
934
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.02%
—
—
—
—
—
—
0
29
99
931
Physiotherapist
Z3226 [2001311560]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.35%
—
—
—
—
—
—
5
13
94
947
budesonide; inhalant
R03BA02 [21603285]
8.2e-01
—
-1.0e+50
—
—
1.0e+00
8.1e-01
cases:8.65%
controls:4.01%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
cases:5.83%
controls:2.15%
cases:9.09%
controls:4.27%
9
41
95
981
—
0
6
105
1023
—
—
6
22
97
1003
9
41
90
919
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
1.6e-01
—
-1.0e+50
—
-1.0e+50
6.3e-01
6.7e-01
cases:7.69%
controls:6.65%
—
—
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.49%
cases:7.77%
controls:4.29%
cases:22.22%
controls:12.71%
8
68
96
954
—
0
6
105
1023
—
0
5
105
1024
8
44
95
981
22
122
77
838
chloramphenicol
S01AA01 [21603554]
3.5e-01
-1.0e+50
—
—
—
—
2.4e-01
cases:4.81%
controls:3.42%
cases:0.00%
controls:1.17%
—
—
—
—
—
—
—
—
cases:7.07%
controls:5.63%
5
35
99
987
0
12
105
1017
—
—
—
—
7
54
92
906
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
dextromethorphan, combinations; oral
N07XX59 [43534835]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.88%
—
—
—
—
—
—
5
18
94
942
Pain localized to upper abdomen
R10.1 [45568111]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
0
5
105
1024
—
—
—
0
7
103
1018
—
Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
H90.4 [45572067]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
99
952
Very demanding periodontal treatment
SDA05 [2001310330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
—
—
—
—
—
8.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:2.60%
—
—
—
—
—
—
6
25
93
935
hydrochlorothiazide; oral
C03AA03 [21601466]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:0.00%
controls:1.17%
—
—
—
—
—
—
0
6
105
1023
0
12
103
1013
—
Cough
R05 [45606792]
1.4e+00
—
—
—
—
—
—
cases:6.73%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
7
18
97
1004
—
—
—
—
—
—
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.88%
—
—
—
—
—
—
5
18
94
942
clidinium and psycholeptics
A03CA02 [21600204]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
99
952
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Thyrotropin receptor Ab [Units/volume] in Serum
5385-0 [3017044]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
3.6e-01
—
—
—
—
—
1.6e-01
cases:5.77%
controls:4.11%
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:5.21%
6
42
98
980
—
—
—
—
—
6
50
93
910
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.5e-01
2.8e-01
—
—
—
1.3e-01
2.9e-01
cases:15.38%
controls:12.43%
cases:13.33%
controls:10.40%
—
—
—
—
—
—
cases:13.59%
controls:12.10%
cases:28.28%
controls:22.81%
16
127
88
895
14
107
91
922
—
—
—
14
124
89
901
28
219
71
741
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
8.9e-03
2.9e-01
—
—
—
2.5e-01
2.0e-01
cases:11.54%
controls:11.45%
cases:10.48%
controls:8.07%
—
—
—
—
—
—
cases:10.68%
controls:8.49%
cases:24.24%
controls:20.83%
12
117
92
905
11
83
94
946
—
—
—
11
87
92
938
24
200
75
760
Fungus identified in Specimen by Culture
580-1 [3000494]
-1.0e+50
-1.0e+50
—
—
—
—
1.5e+00
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:6.06%
controls:1.46%
0
5
104
1017
0
5
105
1024
—
—
—
—
6
14
93
946
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
—
-1.0e+50
—
—
—
-1.0e+50
1.4e+00
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:7.07%
controls:1.77%
—
0
7
105
1022
—
—
—
0
6
103
1019
7
17
92
943
X-linked ichthyosis
Q80.1 [45606775]
—
—
—
1.0e+50
—
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:12.38%
controls:0.00%
—
—
cases:8.74%
controls:0.00%
cases:9.09%
controls:0.00%
—
—
—
13
0
92
1029
—
9
0
94
1025
9
0
90
960
Oral Surgery
19 [38004464]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
104
1013
—
—
—
—
—
—
Excessive ear wax
H81 [2002000536]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
5
103
1020
—
Two-surface restoration
SFA20 [2001310359]
8.5e-03
4.4e-01
-1.0e+50
—
—
7.5e-01
6.1e-01
cases:7.69%
controls:7.63%
cases:4.76%
controls:3.11%
cases:0.00%
controls:0.49%
—
—
—
—
cases:6.80%
controls:3.32%
cases:21.21%
controls:12.71%
8
78
96
944
5
32
100
997
0
5
105
1024
—
—
7
34
96
991
21
122
78
838
Three-surface restoration
SFA30 [2001310360]
—
-1.0e+50
—
—
—
—
2.4e-01
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
cases:8.08%
controls:6.46%
—
0
16
105
1013
—
—
—
—
8
62
91
898
Senile incipient cataract
H25.0 [45576699]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Orthopedic Surgery
20 [38004465]
-3.1e-01
—
—
—
-1.0e+50
4.9e-01
4.9e-01
cases:5.77%
controls:7.73%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
cases:4.85%
controls:3.02%
cases:16.16%
controls:10.52%
6
79
98
943
—
—
—
0
8
105
1021
5
31
98
994
16
101
83
859
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
0
9
104
1013
—
—
—
—
0
6
103
1019
—
Periodontal treatment
SDA03 [2001310328]
—
—
—
—
—
—
-1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:5.73%
—
—
—
—
—
—
5
55
94
905
beclometasone; nasal
R01AD01 [21605043]
1.6e+00
—
—
—
—
—
—
cases:6.73%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
—
—
7
15
97
1007
—
—
—
—
—
—
terbutaline; oral, parenteral
R03CC03 [21603313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
cetirizine; oral
R06AE07 [21603497]
2.9e-01
8.0e-01
—
—
—
5.8e-01
6.6e-01
cases:10.58%
controls:8.12%
cases:6.67%
controls:3.11%
—
—
—
—
—
—
cases:6.80%
controls:3.90%
cases:14.14%
controls:7.81%
11
83
93
939
7
32
98
997
—
—
—
7
40
96
985
14
75
85
885
Emergency Medicine
93 [38004510]
-2.6e-01
1.1e+00
—
—
—
—
9.5e-02
cases:4.81%
controls:6.16%
cases:7.62%
controls:2.72%
—
—
—
—
—
—
—
—
cases:11.11%
controls:10.21%
5
63
99
959
8
28
97
1001
—
—
—
—
11
98
88
862
covid-19, RNA-based vaccine
J07BN01 [954934]
3.5e-01
—
-1.0e+50
—
—
-5.1e-03
2.4e-01
cases:4.81%
controls:3.42%
—
—
cases:0.00%
controls:0.78%
—
—
—
—
cases:4.85%
controls:4.88%
cases:13.13%
controls:10.63%
5
35
99
987
—
0
8
105
1021
—
—
5
50
98
975
13
102
86
858
terbinafine; oral
D01BA02 [21601967]
—
—
—
—
—
—
6.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:2.60%
—
—
—
—
—
—
5
25
94
935
Base excess in Arterial blood by calculation
1925-7 [3003396]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
104
1009
—
—
—
—
—
—
Spontaneous vertex delivery
O80.0 [45577661]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:2.50%
—
—
—
—
—
0
5
103
1020
0
24
99
936
Thyroperoxidase Ab [Units/volume] in Serum or Plasma
8099-4 [3027238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
lisinopril; oral
C09AA03 [21601787]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.52%
0
6
104
1016
—
—
—
—
0
5
103
1020
0
5
99
955
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Other congenital ichthyosis
Q80.8 [45577764]
—
—
—
1.0e+50
—
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:11.43%
controls:0.00%
—
—
cases:9.71%
controls:0.00%
cases:11.11%
controls:0.00%
—
—
—
12
0
93
1029
—
10
0
93
1025
11
0
88
960
pramipexole; oral
N04BC05 [21604477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Other and unspecified ovarian cysts
N83.2 [45539066]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
Sepsis due to other Gram-negative organisms
A41.5 [45556902]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Diabetes insulin dependent
T89 [2002001130]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
0
12
99
948
False labour before 37 completed weeks of gestation
O47.0 [45582556]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Midwife
Z3232 [2001311563]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
0
11
99
949
cyproterone and estrogen
G03HB01 [21602617]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
0
8
105
1021
—
—
—
—
—
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
3.0e-01
4.7e-01
—
—
—
-3.3e-01
4.1e-01
cases:13.46%
controls:10.37%
cases:8.57%
controls:5.54%
—
—
—
—
—
—
cases:4.85%
controls:6.63%
cases:24.24%
controls:17.50%
14
106
90
916
9
57
96
972
—
—
—
5
68
98
957
24
168
75
792
Emergency Room and Inpatient Visit
ERIP [262]
—
—
—
—
—
-1.0e+50
3.4e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.17%
cases:5.05%
controls:3.65%
—
—
—
—
—
0
12
103
1013
5
35
94
925
norethisterone and ethinylestradiol
G03AA05 [21602478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
Nursing episode
950 [44777714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
104
1013
—
—
—
—
—
—
candesartan; oral
C09CA06 [21601829]
—
—
-1.0e+50
—
-1.0e+50
—
2.0e-01
—
—
—
—
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.49%
—
—
cases:5.05%
controls:4.17%
—
—
0
6
105
1023
—
0
5
105
1024
—
5
40
94
920
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:1.98%
—
—
—
—
—
—
6
19
93
941
Other obstetric ultrasound examination
MA2XE [2001306838]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
—
1.5e+00
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.15%
0
5
104
1017
—
—
—
—
—
5
11
94
949
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
2.8e-02
7.1e-01
—
—
—
9.6e-01
5.3e-01
cases:6.73%
controls:6.56%
cases:6.67%
controls:3.40%
—
—
—
—
—
—
cases:7.77%
controls:3.12%
cases:18.18%
controls:11.56%
7
67
97
955
7
35
98
994
—
—
—
8
32
95
993
18
111
81
849
Streptococcal pharyngitis
J02.0 [45533537]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.14%
—
—
—
—
—
—
—
—
—
—
0
22
105
1007
—
—
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
-9.9e-02
—
—
—
—
1.2e+00
5.3e-01
cases:4.81%
controls:5.28%
—
—
—
—
—
—
—
—
cases:6.80%
controls:2.24%
cases:11.11%
controls:6.88%
5
54
99
968
—
—
—
—
7
23
96
1002
11
66
88
894
Migraine with aura [classical migraine]
G43.1 [45562086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
104
1014
—
—
—
—
—
—
Health examination of person liable for military service
SPAT1321 [2001700422]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
9
99
951
promethazine, combinations
R06AD52 [21603489]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.88%
—
—
—
—
—
—
5
18
94
942
Sytologyspecimen from mouth of uterus
XLD00 [2001306651]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Simple extraction of IUD
TLC02 [2001306648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Percutaneous insertion of coronary artery stent
FN1YT [2001303064]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Standard cardiac ultrasound examination
FM1AE [2001303278]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:1.77%
—
—
—
—
—
—
7
17
92
943
naproxen and esomeprazole; oral
M01AE52 [40254096]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
0
7
105
1022
—
—
—
—
0
8
99
952
Cardiac murmur, unspecified
R01.1 [45548943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Contusion of other parts of wrist and hand
S60.2 [45602941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Polysomnography panel
90568-7 [1002224]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
General symptom/complaint other
A29 [2002000163]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.15%
—
—
—
—
—
—
5
11
94
949
Cerebral infarction, unspecified
I63.9 [45596216]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
0
5
105
1024
—
—
—
0
6
103
1019
—
tioconazole; vaginal
G01AF08 [21602398]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
0
14
99
946
Root filling of tooth with onetwo root canals
SGB20 [2001310389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.15%
—
—
—
—
—
—
5
11
94
949
Thorax X-ray examination
GD1AA [2001303617]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:4.38%
—
—
—
—
—
—
11
42
88
918
Sequelae of cerebral infarction
I69.3 [45533476]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
5
103
1020
—
sodium fluoride; oral
A01AA01 [21600005]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
104
1014
—
—
—
—
—
—
scopolamine; oral, parenteral
N05CM05 [21604666]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Rotator cuff syndrome
M75.1 [45596678]
-1.0e+50
-1.0e+50
—
—
—
—
8.7e-01
cases:0.00%
controls:1.57%
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:5.05%
controls:2.19%
0
16
104
1006
0
7
105
1022
—
—
—
—
5
21
94
939
Routine child health examination
Z00.1 [45561606]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.17%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
0
12
104
1010
—
—
—
—
0
5
103
1020
—
macrogol; oral
A06AD15 [21600575]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
rizatriptan; oral
N02CC04 [21604379]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Need for immunization against other specified single viral diseases
Z25.8 [45547296]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.7e-01
6.6e-01
—
—
—
1.2e+00
6.1e-01
cases:5.77%
controls:4.89%
cases:4.76%
controls:2.53%
—
—
—
—
—
—
cases:6.80%
controls:2.05%
cases:11.11%
controls:6.35%
6
50
98
972
5
26
100
1003
—
—
—
7
21
96
1004
11
61
88
899
Open wound of other parts of foot
S91.3 [45599027]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Body CT examination
JN4AD [2001310897]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
9
99
951
brinzolamide, combinations
S01EC54 [45893490]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
99
952
Obstetrics / Gynecology
16 [38004461]
4.5e-01
4.8e-01
—
—
—
—
-3.5e-02
cases:16.35%
controls:11.06%
cases:4.76%
controls:3.01%
—
—
—
—
—
—
—
—
cases:11.11%
controls:11.46%
17
113
87
909
5
31
100
998
—
—
—
—
11
110
88
850
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
4.1e-01
9.2e-01
—
—
—
—
7.8e-01
cases:5.77%
controls:3.91%
cases:4.76%
controls:1.94%
—
—
—
—
—
—
—
—
cases:9.09%
controls:4.38%
6
40
98
982
5
20
100
1009
—
—
—
—
9
42
90
918
Treatment plan or consultation
WZC00 [2001310885]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
0
14
103
1011
—
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
0
6
103
1019
—
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
—
—
-1.0e+50
—
-1.0e+50
—
-3.2e-02
—
—
—
—
cases:0.00%
controls:0.78%
—
—
cases:0.00%
controls:0.68%
—
—
cases:5.05%
controls:5.21%
—
—
0
8
105
1021
—
0
7
105
1022
—
5
50
94
910
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
2.4e-01
—
—
—
—
—
1.7e-01
cases:7.69%
controls:6.16%
—
—
—
—
—
—
—
—
—
—
cases:8.08%
controls:6.88%
8
63
96
959
—
—
—
—
—
8
66
91
894
Acute upper respiratory infections of multiple and unspecified sites
J06 [45601116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
folic acid
V04CX02 [715877]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
erythromycin; oral, parenteral
J01FA01 [21602970]
6.2e-01
—
—
—
—
—
-1.0e+50
cases:4.81%
controls:2.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
5
27
99
995
—
—
—
—
—
0
8
99
952
Other complicated root filling
SGB30 [2001310390]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
104
1015
—
—
—
—
—
—
Endocrinology
46 [38004485]
—
—
-1.0e+50
—
-1.0e+50
—
5.3e-01
—
—
—
—
cases:0.00%
controls:0.49%
—
—
cases:0.00%
controls:0.49%
—
—
cases:5.05%
controls:3.02%
—
—
0
5
105
1024
—
0
5
105
1024
—
5
29
94
931
Elevated blood pressure
K85 [2002000612]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
104
1013
—
—
—
—
—
—
12 lead EKG panel
34534-8 [3044889]
5.0e-01
—
—
—
—
—
2.8e-01
cases:11.54%
controls:7.34%
—
—
—
—
—
—
—
—
—
—
cases:16.16%
controls:12.71%
12
75
92
947
—
—
—
—
—
16
122
83
838
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
0
18
99
942
Heart failure, unspecified
I50.9 [45576879]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
5
103
1020
—
Diabetes mellitus screening
171183004 [4064918]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
0
5
105
1024
—
—
—
—
0
5
99
955
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
3.8e-01
—
—
—
-1.0e+50
—
4.1e-01
cases:4.81%
controls:3.33%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
cases:8.08%
controls:5.52%
5
34
99
988
—
—
—
0
5
105
1024
—
8
53
91
907
flucloxacillin; oral, parenteral
J01CF05 [21602857]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
citalopram; oral, parenteral
N06AB04 [21604712]
1.1e+00
—
-1.0e+50
—
—
—
5.3e-01
cases:7.69%
controls:2.64%
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:6.06%
controls:3.65%
8
27
96
995
—
0
6
105
1023
—
—
—
6
35
93
925
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
—
—
—
—
—
8.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:2.71%
—
—
—
—
—
—
6
26
93
934
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.63%
—
—
—
—
—
0
5
103
1020
0
6
99
954
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
6.6e-01
—
—
—
—
—
3.9e-01
cases:4.81%
controls:2.54%
—
—
—
—
—
—
—
—
—
—
cases:8.08%
controls:5.63%
5
26
99
996
—
—
—
—
—
8
54
91
906
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
1.2e+00
—
—
—
—
—
—
cases:4.81%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
—
—
5
15
99
1007
—
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
99
952
Albumin [Mass/volume] in Urine
1754-1 [3012516]
5.1e-01
—
—
—
—
—
3.7e-01
cases:4.81%
controls:2.94%
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:5.00%
5
30
99
992
—
—
—
—
—
7
48
92
912
Neurosurgery
14 [38004459]
8.8e-01
—
—
—
—
—
—
cases:4.81%
controls:2.05%
—
—
—
—
—
—
—
—
—
—
—
—
5
21
99
1001
—
—
—
—
—
—
Fitting and adjustment of other specified devices
Z46.8 [45581035]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
—
—
—
—
—
—
3.3e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:4.90%
—
—
—
—
—
—
5
47
94
913
Root filling of tooth with one root canal
SGB10 [2001310388]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
5
105
1024
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-8.2e-03
-1.7e-01
—
—
—
1.7e-01
1.9e-01
cases:9.62%
controls:9.69%
cases:6.67%
controls:7.77%
—
—
—
—
—
—
cases:10.68%
controls:9.17%
cases:20.20%
controls:17.29%
10
99
94
923
7
80
98
949
—
—
—
11
94
92
931
20
166
79
794
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
-2.1e-01
—
—
—
—
7.5e-01
4.2e-01
cases:4.81%
controls:5.87%
—
—
—
—
—
—
—
—
cases:5.83%
controls:2.83%
cases:11.11%
controls:7.60%
5
60
99
962
—
—
—
—
6
29
97
996
11
73
88
887
Bacteria identified in Stool by Culture
625-4 [3025941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
pH of Serum or Plasma
2753-2 [3018418]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:3.54%
—
—
—
—
—
—
6
34
93
926
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
0
11
99
949
varicella, live attenuated
J07BK01 [21601362]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Aortic (valve) insufficiency
I35.1 [45572087]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Spirometry study
18759-1 [3000492]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
104
1013
—
—
—
—
—
—
etoricoxib; oral
M01AH05 [21603996]
2.5e-01
—
—
—
—
—
6.6e-01
cases:8.65%
controls:6.85%
—
—
—
—
—
—
—
—
—
—
cases:14.14%
controls:7.81%
9
70
95
952
—
—
—
—
—
14
75
85
885
Methemoglobin/Hemoglobin.total in Blood
2614-6 [3007930]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.4e-01
9.7e-02
—
—
—
2.2e-01
2.4e-01
cases:15.38%
controls:13.70%
cases:12.38%
controls:11.37%
—
—
—
—
—
—
cases:15.53%
controls:12.88%
cases:30.30%
controls:25.52%
16
140
88
882
13
117
92
912
—
—
—
16
132
87
893
30
245
69
715
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.2e-01
2.3e-01
—
—
8.3e-01
3.4e-01
2.1e-01
cases:17.31%
controls:15.66%
cases:15.24%
controls:12.54%
—
—
—
—
cases:6.67%
controls:3.01%
cases:18.45%
controls:13.85%
cases:33.33%
controls:28.75%
18
160
86
862
16
129
89
900
—
—
7
31
98
998
19
142
84
883
33
276
66
684
venlafaxine; oral
N06AX16 [21604745]
1.7e+00
—
—
—
—
—
—
cases:5.77%
controls:1.08%
—
—
—
—
—
—
—
—
—
—
—
—
6
11
98
1011
—
—
—
—
—
—
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Treatment of a patient needing special arrangements
WYA30 [2001310874]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
Bacteria identified in Isolate by Culture
43409-2 [3042936]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
5
103
1020
—
Single live birth
Z37.0 [45571346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
9
99
951
Disturbance of activity and attention
F90.0 [45542870]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
5
105
1024
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
—
—
—
—
1.1e+00
7.8e-01
—
—
—
—
—
—
—
—
—
—
cases:7.77%
controls:2.83%
cases:9.09%
controls:4.38%
—
—
—
—
—
8
29
95
996
9
42
90
918
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:3.13%
—
—
—
—
—
—
5
30
94
930
Respiratory infection other
R83 [2002000951]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.67%
0
12
104
1010
—
—
—
—
—
0
16
99
944
Female infertility, unspecified
N97.9 [45582432]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]
2.8e-01
—
—
—
—
—
3.6e-01
cases:6.73%
controls:5.19%
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:8.02%
7
53
97
969
—
—
—
—
—
11
77
88
883
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.1e-01
4.7e-01
—
—
—
6.7e-01
5.1e-01
cases:11.54%
controls:9.59%
cases:8.57%
controls:5.54%
—
—
—
—
—
—
cases:11.65%
controls:6.34%
cases:26.26%
controls:17.60%
12
98
92
924
9
57
96
972
—
—
—
12
65
91
960
26
169
73
791
tretinoin, combinations; ointment
D10AD51 [21602298]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Follow-up examination after treatment of fracture
Z09.4 [45561611]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
7
104
1015
—
—
—
—
—
0
5
99
955
Toxoplasma gondii IgG Ab [Units/volume] in Serum
8039-0 [3014959]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.46%
—
—
—
—
—
—
5
14
94
946
Exposure to unspecified factor
X59 [45756412]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
0
7
105
1022
—
—
—
—
—
Nonallergic asthma
J45.1 [45557625]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.77%
—
—
—
—
—
—
0
17
99
943
medroxyprogesterone; oral, parenteral
L02AB02 [21603821]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Other chronic periodontitis
K05.38 [2000502732]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
5.2e-01
7.0e-01
—
—
-1.0e+50
7.2e-01
7.3e-01
cases:9.62%
controls:5.97%
cases:5.71%
controls:2.92%
—
—
—
—
cases:0.00%
controls:0.78%
cases:5.83%
controls:2.93%
cases:17.17%
controls:9.06%
10
61
94
961
6
30
99
999
—
—
0
8
105
1021
6
30
97
995
17
87
82
873
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
104
1009
—
—
—
—
—
—
Ultrasound screening of fetal nuchal translucency
MA2JE [2001306837]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
99
952
Acute spinal anesthesia for delivery
WX321 [2001310800]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
Gastro-oesophageal reflux disease
K21 [45586708]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Coeliac disease
K90.0 [45586745]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
Urinary frequency/urgency
U02 [2002001138]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
—
—
—
—
—
—
8.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:2.19%
—
—
—
—
—
—
5
21
94
939
Supervision of normal pregnancy
Z34 [45566419]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
insulin aspart; parenteral
A10AB05 [21600719]
—
—
-1.0e+50
—
—
—
-3.2e-02
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:5.05%
controls:5.21%
—
—
0
6
105
1023
—
—
—
5
50
94
910
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
—
—
—
—
—
—
5.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:4.06%
—
—
—
—
—
—
7
39
92
921
metronidazole; oral, rectal
P01AB01 [21604857]
—
—
—
—
—
—
4.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:3.96%
—
—
—
—
—
—
6
38
93
922
carbimazole; oral
H03BB01 [21602765]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
Asthma
R96 [2002000961]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
104
1013
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.01 [2000501514]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.66%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
104
1005
—
—
—
—
—
—
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
-4.5e-01
2.3e-01
-1.0e+50
—
-1.0e+50
5.0e-01
1.1e-01
cases:4.81%
controls:7.34%
cases:7.62%
controls:6.12%
cases:0.00%
controls:0.58%
—
—
cases:0.00%
controls:0.68%
cases:11.65%
controls:7.41%
cases:15.15%
controls:13.75%
5
75
99
947
8
63
97
966
0
6
105
1023
—
0
7
105
1022
12
76
91
949
15
132
84
828
fluticasone; inhalant
R03BA05 [21603288]
7.4e-01
—
—
—
-1.0e+50
—
3.1e-01
cases:5.77%
controls:2.84%
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
cases:5.05%
controls:3.75%
6
29
98
993
—
—
—
0
8
105
1021
—
5
36
94
924
The fear of childbirth
O99.80 [2000503219]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Fever
A03 [2002000144]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
0
13
104
1009
0
5
105
1024
—
—
—
0
6
103
1019
—
Disease/condition unspecnature/site
A99 [2002000232]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
0
10
99
950
Low back pain
M54.5 [45553207]
7.8e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:4.81%
controls:2.25%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
cases:10.10%
controls:3.65%
5
23
99
999
0
5
105
1024
—
—
—
—
10
35
89
925
Peritonsillar abscess
J36 [45581858]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Ultrasound measurement of residual urine
KC1EE [2001305918]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.08%
—
0
7
105
1022
—
—
—
—
0
20
99
940
fusidic acid
D09AA02 [21602265]
1.1e+00
—
—
—
—
—
1.3e+00
cases:6.73%
controls:2.35%
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:1.98%
7
24
97
998
—
—
—
—
—
7
19
92
941
Tear of meniscus, current
S83.2 [45555441]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
0
8
99
952
Phosphatidylethanol [Mass/volume] in Blood
74661-0 [44816559]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
metronidazole; vaginal
G01AF01 [21602392]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
104
1007
—
—
—
—
—
—
Headache
N01 [2002000720]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
0
6
104
1016
—
—
—
—
0
6
103
1019
—
Chronic maxillary sinusitis
J32.0 [45586667]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
104
1014
—
—
—
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
0
5
105
1024
—
—
—
0
7
103
1018
—
Split tooth for reasons other than trauma
K03.82 [2000502700]
—
—
—
—
—
—
5.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:2.92%
—
—
—
—
—
—
5
28
94
932
scopolamine
A04AD01 [21600499]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
ranitidine bismuth citrate; oral
A02BA07 [21600088]
—
—
—
—
—
-1.0e+50
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:6.06%
controls:1.46%
—
—
—
—
—
0
7
103
1018
6
14
93
946
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
-1.0e+50
—
—
—
—
—
1.1e+00
cases:0.00%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.67%
0
15
104
1007
—
—
—
—
—
5
16
94
944
Shoulder symptom/complaint
L08 [2002000632]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.47%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
0
15
104
1007
0
5
105
1024
—
—
—
—
—
Dyspnoea
R06.0 [45558449]
—
—
—
—
—
—
6.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:3.33%
—
—
—
—
—
—
6
32
93
928
eletriptan; oral
N02CC06 [21604381]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
tiotropium bromide; inhalant
R03BB04 [21603296]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
—
—
cases:5.05%
controls:1.35%
—
0
9
105
1020
—
—
—
—
5
13
94
947
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
4.0e-01
—
—
—
—
—
—
cases:6.73%
controls:4.60%
—
—
—
—
—
—
—
—
—
—
—
—
7
47
97
975
—
—
—
—
—
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
1.4e-01
3.6e-01
—
—
—
3.1e-01
5.2e-02
cases:12.50%
controls:11.06%
cases:8.57%
controls:6.12%
—
—
—
—
—
—
cases:8.74%
controls:6.54%
cases:20.20%
controls:19.38%
13
113
91
909
9
63
96
966
—
—
—
9
67
94
958
20
186
79
774
Hepatitis B virus surface Ab [Units/volume] in Serum
16935-9 [3023421]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.05%
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
0
21
104
1001
0
5
105
1024
—
—
—
—
—
Examination for driving licence
Z02.4 [45552056]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
5
103
1020
—
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.2e-01
2.3e-01
—
—
8.3e-01
3.6e-01
2.2e-01
cases:17.31%
controls:15.66%
cases:15.24%
controls:12.54%
—
—
—
—
cases:6.67%
controls:3.01%
cases:18.45%
controls:13.66%
cases:33.33%
controls:28.65%
18
160
86
862
16
129
89
900
—
—
7
31
98
998
19
140
84
885
33
275
66
685
Myalgia
M79.1 [45587062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
Obstetric epidural analgesia
WX307 [2001310797]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
Atherosclerosis of arteries of extremities
I70.2 [45538421]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
5
103
1020
—
lansoprazole; oral
A02BC03 [21600098]
5.8e-01
—
—
—
—
-1.0e+50
—
cases:4.81%
controls:2.74%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
5
28
99
994
—
—
—
—
0
13
103
1012
—
Catheterisation of bladder
TKC20 [2001306020]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
0
5
105
1024
—
—
—
—
—
Sampling
SPAT1263 [2001700364]
—
1.1e+00
—
—
—
9.4e-01
4.6e-01
—
—
cases:5.71%
controls:1.94%
—
—
—
—
—
—
cases:4.85%
controls:1.95%
cases:9.09%
controls:5.94%
—
6
20
99
1009
—
—
—
5
20
98
1005
9
57
90
903
fluticasone furoate
R03BA09 [45893496]
5.8e-01
—
—
—
-1.0e+50
—
3.1e-01
cases:4.81%
controls:2.74%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
cases:5.05%
controls:3.75%
5
28
99
994
—
—
—
0
7
105
1022
—
5
36
94
924
Obesity due to excess calories
E66.01 [2000501501]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
9
99
951
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
5.3e-01
1.8e-01
—
—
—
3.5e-01
4.0e-01
cases:15.38%
controls:9.69%
cases:6.67%
controls:5.64%
—
—
—
—
—
—
cases:8.74%
controls:6.34%
cases:24.24%
controls:17.60%
16
99
88
923
7
58
98
971
—
—
—
9
65
94
960
24
169
75
791
Antenatal screening for malformation
717800004 [36713462]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:2.60%
—
0
5
105
1024
—
—
—
0
5
103
1020
0
25
99
935
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
1.2e+00
—
—
—
—
—
5.3e-01
cases:4.81%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:3.02%
5
16
99
1006
—
—
—
—
—
5
29
94
931
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.52%
—
0
7
105
1022
—
—
—
0
6
103
1019
0
5
99
955
Emergency care or similar visit
WYA10 [2001310872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
Other and unspecified abdominal pain
R10.4 [45568113]
4.5e-01
—
—
—
—
—
4.1e-02
cases:4.81%
controls:3.13%
—
—
—
—
—
—
—
—
—
—
cases:6.06%
controls:5.83%
5
32
99
990
—
—
—
—
—
6
56
93
904
Blood test
-34 [2002000105]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
99
955
pH of Venous blood
2746-6 [3012544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
104
1017
—
—
—
—
—
—
risperidone; oral, parenteral
N05AX08 [21604559]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.05%
controls:0.94%
—
—
—
—
—
—
5
9
94
951
Basophils [#/volume] in Blood
26444-0 [3006315]
-1.2e-01
—
—
—
—
1.2e+00
4.8e-01
cases:4.81%
controls:5.38%
—
—
—
—
—
—
—
—
cases:6.80%
controls:2.24%
cases:11.11%
controls:7.19%
5
55
99
967
—
—
—
—
7
23
96
1002
11
69
88
891
Emergency Room Visit
ER [9203]
2.7e-01
8.8e-01
—
—
—
8.1e-01
6.0e-01
cases:30.77%
controls:25.24%
cases:20.95%
controls:9.91%
—
—
—
—
—
—
cases:16.50%
controls:8.10%
cases:44.44%
controls:30.52%
32
258
72
764
22
102
83
927
—
—
—
17
83
86
942
44
293
55
667
Spondylolisthesis
M43.1 [45606219]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
104
1016
—
—
—
—
—
—
carvedilol; oral
C07AG02 [21601700]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
6
99
954
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
0
7
99
953
phenoxymethylpenicillin; oral
J01CE02 [21602842]
5.0e-01
—
—
—
-1.0e+50
6.7e-01
1.5e-01
cases:18.27%
controls:11.94%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:4.85%
controls:2.54%
cases:14.14%
controls:12.40%
19
122
85
900
—
—
—
0
5
105
1024
5
26
98
999
14
119
85
841

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
17
40
4.83
7.03
1.2
1.4
—
—
—
0
0
29
115
3.05
5.69
1.5
1.4
—
—
—
0
0
28
115
2.91
5.13
2.8
1.7
—
—
—
0
0
68
441
2.36
4.69
12.7
8.1
1.20
1.21
mmol/l
1.12
60
387
52
325
2.11
3.66
12.2
8.7
—
—
—
0
0
46
277
2.11
3.55
7.8
7.7
—
—
—
0
0
27
135
2.31
3.25
3.3
2.0
—
—
—
0
0
72
526
2.02
3.15
11.7
8.8
0.23
0.19
e9/l
0.89
67
470
10
26
4.11
3.06
1.7
1.7
22.88
24.40
mmol/l
—
10
26
18
78
2.56
2.93
9.8
5.6
0.00
0.14
%
—
6
21
42
261
1.97
2.87
7.0
3.7
7.40
7.39
ph
1.73
32
178
51
339
1.92
2.86
5.8
3.9
41.83
76.04
e6/l
0.51
38
227
19
86
2.45
2.83
9.3
5.3
0.57
0.87
%
—
7
30
92
752
2.20
2.75
5.6
4.0
14.55
14.80
pmol/l
0.43
87
689
6
10
6.26
2.73
3.3
1.9
30.17
31.90
pg
—
6
10
88
716
2.04
2.53
13.6
8.4
89.69
83.93
u/l
0.40
88
673
18
84
2.36
2.51
9.8
5.9
0.00
0.38
%
—
6
24
18
84
2.36
2.51
9.6
5.4
0.17
0.48
%
—
6
28
25
135
2.09
2.47
13.6
6.6
1.16
1.11
mmol/l
0.31
25
126
44
300
1.76
2.15
4.6
3.1
16.02
47.48
e6/l
1.12
38
220
7
20
3.66
2.09
6.7
2.4
7.39
7.43
ph
—
7
20
7
21
3.48
2.00
2.6
2.2
—
—
—
0
0
25
146
1.91
1.99
8.1
4.4
0.78
0.82
mmol/l
0.99
25
139
36
237
1.76
1.96
3.3
2.9
—
—
—
0
0
6
16
3.90
1.96
4.3
2.4
14.58
9.21
pmol/l
—
6
16
39
268
1.70
1.81
2.5
1.6
2.41
2.34
g/l
0.10
24
157
41
286
1.68
1.80
3.0
3.5
—
—
—
0
0
18
97
2.02
1.78
1.4
1.1
—
—
—
0
0
0
46
0.00
1.75
0.0
1.1
—
0.91
—
0
46
104
945
2.26
1.70
30.1
15.8
3.97
3.95
mmol/l
0.27
104
925
104
945
2.26
1.70
29.9
15.7
140.05
139.60
mmol/l
1.38
104
927
14
70
2.14
1.67
2.9
1.2
—
—
—
0
0
16
87
1.98
1.55
5.8
3.5
10.85
10.22
g/l
0.31
16
81
0
45
0.00
1.54
0.0
1.1
—
0.61
—
0
6
99
886
1.95
1.53
6.7
5.0
2.28
1.87
mu/l
2.12
93
818
56
437
1.56
1.51
20.6
12.2
0.00
0.00
e9/l
0.50
51
357
36
254
1.61
1.48
5.2
3.0
0.35
0.20
e6/l
0.31
31
176
45
336
1.56
1.46
3.1
1.9
—
—
—
0
0
5
16
3.22
1.45
1.4
1.6
87.54
92.13
%
—
5
16
5
16
3.22
1.45
1.2
1.3
—
—
—
0
0
41
302
1.56
1.40
1.6
1.5
5.01
1.74
u/ml
—
10
67
75
631
1.56
1.40
6.6
4.2
—
—
—
0
0
12
61
2.08
1.38
3.0
3.5
7.39
7.42
ph
1.01
12
51
5
17
3.03
1.37
2.2
1.3
—
—
—
0
0
15
84
1.91
1.35
3.8
4.2
57.63
72.71
e9/l
—
10
61
33
233
1.59
1.34
10.3
4.7
—
—
—
0
0
11
55
2.11
1.32
11.0
3.6
1.22
1.23
mmol/l
0.20
11
45
9
166
0.50
1.32
1.7
1.8
—
—
—
0
0
9
44
2.13
1.30
3.7
3.6
—
—
—
0
0
9
44
2.13
1.30
9.7
12.5
23.96
24.74
mmol/l
—
9
44
13
70
1.97
1.30
4.7
2.4
63.94
67.38
g/l
0.72
13
64
39
289
1.53
1.28
3.3
2.6
—
—
—
0
0
13
71
1.94
1.25
4.7
2.1
0.80
1.20
g/l
1.25
13
66
16
94
1.82
1.25
11.2
9.2
—
—
—
0
0
18
110
1.76
1.24
7.6
7.5
1.84
1.26
mmol/l
0.48
13
91
14
80
1.86
1.19
11.6
10.1
7.41
7.43
ph
—
6
44
38
285
1.50
1.17
3.1
2.2
172.71
224.63
u/l
0.32
38
274
52
418
1.45
1.13
5.1
3.2
5.98
6.19
ph
0.76
29
226
40
306
1.48
1.12
3.8
3.4
7.68
8.00
mmol/l
0.18
34
267
34
252
1.50
1.10
4.7
4.4
13.47
10.38
mg/mmol
0.10
22
159
23
157
1.58
1.07
2.7
2.4
2.47
2.43
mmol/l
0.64
23
137
52
422
1.43
1.06
4.1
3.1
—
—
estimate
—
0
0
28
201
1.52
1.05
2.1
2.1
1.43
1.07
mg/l
0.42
20
153
62
520
1.43
1.05
6.1
3.6
0.00
0.00
estimate
-0.00
13
85
18
116
1.66
1.04
1.4
1.6
—
—
—
0
0
5
22
2.33
1.04
7.0
2.6
64.82
57.75
%
—
5
22
5
22
2.33
1.04
1.0
1.5
16.78
10.98
mg/l
—
5
22
5
22
2.33
1.04
1.8
1.2
—
—
—
0
0
9
48
1.95
1.03
14.0
12.8
0.62
0.65
%
—
9
48
33
247
1.47
1.02
4.2
3.8
64.26
66.25
mg/l
0.01
23
161
7
35
2.06
1.02
1.3
1.0
3.26
0.75
u/ml
—
7
18
9
49
1.91
1.01
14.8
12.7
1.20
1.46
%
—
9
49
7
36
2.01
0.99
1.3
1.0
3.59
9.15
u/ml
—
7
24
18
118
1.62
0.98
1.3
1.2
—
—
—
0
0
49
401
1.39
0.92
2.4
1.9
1.23
1.41
mmol/l
0.92
41
338
22
154
1.53
0.92
3.0
3.0
1.24
2.23
e6/l
0.55
14
76
93
851
1.52
0.91
7.7
5.6
38.81
38.46
mmol/mol
0.13
88
803
60
510
1.38
0.89
5.5
3.5
0.00
0.00
estimate
-0.00
14
91
11
65
1.77
0.86
2.5
2.1
17.15
4.48
ug/l
0.43
11
59
12
74
1.70
0.82
6.6
8.6
23.92
24.03
mmol/l
0.05
12
74
5
23
2.23
0.77
2.4
1.5
—
—
—
0
0
32
253
1.37
0.72
4.8
2.9
—
—
estimate
—
0
0
59
513
1.31
0.70
5.6
3.6
99.07
0.00
estimate
0.48
15
94
7
42
1.71
0.70
8.4
5.1
—
—
—
0
0
10
62
1.67
0.67
1.6
1.3
—
—
—
0
0
22
165
1.41
0.67
8.4
3.1
26.94
66.61
ng/l
0.94
17
111
6
105
0.55
0.65
1.7
1.4
—
—
—
0
0
44
371
1.30
0.64
2.1
1.9
100.31
94.53
pmol/l
0.54
36
183
16
114
1.47
0.63
12.6
10.7
103.38
104.06
mmol/l
0.30
16
114
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
17
127
1.40
0.53
2.6
1.4
889.57
1219.32
nmol/l
1.22
17
88
11
75
1.52
0.53
11.0
13.5
24.09
25.59
mmol/l
0.80
11
75
34
400
0.79
0.52
3.2
2.9
—
—
—
0
0
5
81
0.60
0.48
2.4
1.7
—
—
—
0
0
10
69
1.49
0.46
10.0
3.9
207.30
78.19
ng/l
—
10
61
8
55
1.49
0.44
3.9
3.7
4.76
4.62
pmol/l
—
8
49
8
55
1.49
0.44
1.5
1.3
—
—
—
0
0
8
57
1.43
0.43
5.4
9.1
0.63
0.59
%
—
8
57
5
33
1.54
0.42
16.6
5.6
37.24
36.99
°c
—
5
33
0
15
0.00
0.41
0.0
4.5
—
—
—
0
0
15
115
1.35
0.41
1.2
1.2
—
—
—
0
0
21
170
1.29
0.41
4.9
2.5
247.87
105.71
ug/g
0.71
16
141
0
17
0.00
0.41
0.0
3.5
—
59.76
—
0
17
5
76
0.64
0.37
2.4
1.7
—
—
—
0
0
5
80
0.61
0.37
2.4
1.7
—
—
—
0
0
5
80
0.61
0.37
2.4
1.7
—
—
—
0
0
5
80
0.61
0.37
2.4
1.7
—
—
—
0
0
100
965
1.32
0.35
30.1
14.3
19.26
22.67
mg/l
0.74
92
742
7
54
1.32
0.31
1.1
1.1
—
—
—
0
0
27
237
1.18
0.26
11.1
5.6
—
—
—
0
0
9
73
1.25
0.26
8.4
3.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
3.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
106
1071
0.83
0.18
40.7
21.7
133.42
137.89
g/l
2.28
106
1059
106
1070
0.85
0.18
40.2
21.4
29.98
30.19
pg
0.72
106
1059
106
1070
0.85
0.18
41.2
22.2
39.66
41.17
%
1.93
106
1058
7
61
1.16
0.18
1.3
1.1
—
—
—
0
0
106
1069
0.86
0.18
40.3
21.5
89.84
90.17
fl
0.31
106
1058
20
177
1.16
0.18
1.6
1.4
20.48
7.46
u/ml
—
5
76
32
294
1.12
0.17
1.5
1.5
—
—
—
0
0
32
296
1.11
0.15
2.4
2.2
—
—
—
0
0
104
1021
1.23
0.13
31.5
17.0
88.10
75.04
umol/l
0.79
104
1006
32
298
1.10
0.13
4.9
2.8
0.00
0.00
estimate
—
10
76
98
997
0.87
0.12
24.8
11.7
—
—
—
0
0
21
193
1.11
0.11
1.8
1.4
15.38
25.62
iu/ml
—
8
59
6
55
1.10
0.09
1.0
1.1
—
—
—
0
0
35
333
1.07
0.09
5.1
3.2
24.70
34.33
ng/l
0.38
27
207
26
273
0.94
0.06
6.5
3.5
0.00
0.00
estimate
-0.00
12
89
40
387
1.05
0.05
5.6
3.4
0.00
0.00
estimate
-0.00
11
77
10
110
0.90
0.05
2.0
1.4
—
—
—
0
0
25
241
1.05
0.03
6.2
3.7
1.02
1.02
kg/l
0.20
16
152
16
166
0.96
0.00
1.7
2.0
—
—
—
0
0
19
185
1.03
0.00
2.5
1.7
—
—
—
0
0
22
225
0.97
0.00
2.5
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
10.4
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
67.60
—
0
5
0
5
0.00
0.00
0.0
1.6
—
71.40
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
1.19
—
0
5
0
5
0.00
0.00
0.0
3.8
—
28.40
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.0
—
37.78
—
0
9
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.7
—
—
—
0
0
6
64
0.93
-0.00
5.5
1.9
18.47
22.05
iu/l
—
6
52
0
9
0.00
-0.00
0.0
1.6
—
1.00
—
0
9
82
820
1.00
-0.00
30.9
18.7
13.57
13.36
%
0.85
82
814
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
8.0
—
8.78
—
0
9

Mortality – FinRegistry

↥

Association

Association between endpoint Q17_CONGEN_ICHTHYOSIS and mortality.

Females

Parameter HR [95% CI] p-value
Q17_CONGEN_ICHTHYOSIS 2.725 [1.83, 4.05] < 0.001
Birth year 0.999 [0.99, 1.01] 0.719

During the follow-up period (1.1.1998 — 31.12.2019), 56 out of 389 females with Q17_CONGEN_ICHTHYOSIS died.

Males

Parameter HR [95% CI] p-value
Q17_CONGEN_ICHTHYOSIS 2.096 [1.48, 2.97] < 0.001
Birth year 0.987 [0.98, 1.0] 0.009

During the follow-up period (1.1.1998 — 31.12.2019), 86 out of 677 males with Q17_CONGEN_ICHTHYOSIS died.

Mortality risk

Mortality risk for people of age

years, who have Q17_CONGEN_ICHTHYOSIS.

N-year risk Females Males
1 0.288% 0.393%
5 1.607% 2.023%
10 3.991% 5.884%
15 8.222% 11.596%
20 14.303% 19.161%

Relationships between endpoints

↥

Index endpoint: Q17_CONGEN_ICHTHYOSIS – Congenital ichthyosis

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data